CA13

Carbonic anhydrase 13 · Q8N1Q1 · CA13 on Sugi Atlas →

66,320 patent compounds predicted against CA13, 41,310 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Benzthiazide (SCHEMBL198231)	0.39	10/20
Benzthiazide (SCHEMBL26257)	0.42	9/20
Fraxetin (SCHEMBL43472)	1.00	7/20
SCHEMBL112773	0.53	7/20
SCHEMBL228969	0.55	6/20
SCHEMBL229100	0.52	6/20
SCHEMBL36242	0.50	6/20
SCHEMBL16810	0.42	6/20
Scopoletin (SCHEMBL147702)	1.00	5/20
Benzthiazide (SCHEMBL26258)	0.42	5/20
Acetazolamide (SCHEMBL23219)	1.00	4/20
Dichlorphenamide (SCHEMBL112376)	1.00	4/20
Acetazolamide (SCHEMBL40812)	0.97	4/20
Methoxsalen (SCHEMBL19168)	0.62	4/20
Esculetin (SCHEMBL165749)	0.58	4/20
SCHEMBL229073	0.55	4/20
SCHEMBL52075	0.52	4/20
SCHEMBL89928	0.51	4/20
SCHEMBL153334	0.48	4/20
SCHEMBL223287	0.48	4/20

Clinical trials — most relevant to CA13 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer	PHASE3	COMPLETED
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo	PHASE3	COMPLETED
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer	PHASE3	RECRUITING
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status	PHASE2	RECRUITING
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies	PHASE2	WITHDRAWN
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy	PHASE2	RECRUITING
Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model	PHASE1/PHASE2	UNKNOWN
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer	PHASE2	RECRUITING
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy	PHASE2	UNKNOWN
REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression	PHASE2	COMPLETED
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers	PHASE1	COMPLETED
The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.	nan	COMPLETED
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome	nan	UNKNOWN
The Etiology and Progression of Brain Tumors	nan	COMPLETED
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin	nan	UNKNOWN
Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis	nan	COMPLETED
Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer	nan	UNKNOWN
A Prospective Longitudinal Breast Cancer Study	nan	COMPLETED
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer	nan	COMPLETED
Cultured Circulating Tumor Cells in Prostate and Other Cancers	nan	UNKNOWN
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer	nan	WITHDRAWN
Detection of Plasma Circulating Tumor DNA in Gastric Cancer	nan	UNKNOWN
Analysis the Positive Rate of Tumor Markers Among Physical Examination Population	nan	COMPLETED
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder	nan	COMPLETED
Carbohydrate Antigen 19-9 in Colorectal Cancer	nan	UNKNOWN
Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients	nan	COMPLETED
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer	nan	COMPLETED
Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers	nan	RECRUITING
Post-operative Monitoring of Gastric Cancer	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CA13 binder may also engage these)

Protein	Name	Similarity
Q9D6N1	—	1.000	Q9D6N1 →
CA3	Carbonic anhydrase 3	0.999	landscape →
Q9ERQ8	—	0.992	Q9ERQ8 →
P48282	—	0.991	P48282 →
P27139	—	0.991	P27139 →
P07630	—	0.991	P07630 →
P00920	—	0.990	P00920 →
P00919	—	0.990	P00919 →
CA7	Carbonic anhydrase 7	0.989	landscape →
CA2	Carbonic anhydrase 2	0.988	landscape →
Q5S1S4	—	0.987	Q5S1S4 →
Q8HY33	—	0.987	Q8HY33 →
P35217	—	0.987	P35217 →
P00921	—	0.987	P00921 →
P07450	—	0.987	P07450 →
P00917	—	0.986	P00917 →
P00922	—	0.986	P00922 →
P16015	—	0.986	P16015 →
P13634	—	0.985	P13634 →
Q1LZA1	—	0.985	Q1LZA1 →
B0BNN3	—	0.984	B0BNN3 →
Q3SZX4	—	0.984	Q3SZX4 →
Q92051	—	0.984	Q92051 →
P07452	—	0.983	P07452 →
Q8UWA5	—	0.983	Q8UWA5 →
P00916	—	0.982	P00916 →
P14141	—	0.981	P14141 →
P83299	—	0.980	P83299 →
Q7M316	—	0.976	Q7M316 →
CA1	Carbonic anhydrase 1	0.974	landscape →